The Zhitong Finance App learned that Novo Nordisk (NVO.US) opened low and went low. As of press release, it had fallen by more than 8%. According to news, Novo Nordisk held “Capital Markets Day” (CMD) in London on September 21, promising to launch more than five major drugs in the next few years and achieve additional sales of more than 23 billion US dollars. However, its sales target of 23 billion US dollars seems to fall short of market expectations. The company laid off 13,000 employees over the past year and continued to cut costs. Whether the core drug Cagrisema can finally deliver commercial value and whether it can establish a new growth curve is still the focus of the capital market's next focus.

The Zhitong Finance App learned that Novo Nordisk (NVO.US) opened low and went low. As of press release, it had fallen by more than 8%. According to news, Novo Nordisk held “Capital Markets Day” (CMD) in London on September 21, promising to launch more than five major drugs in the next few years and achieve additional sales of more than 23 billion US dollars. However, its target sales of 23 billion US dollars seems to fall short of market expectations. The company laid off 13,000 employees over the past year and continued to cut costs. Whether the core drug Cagrisema can finally deliver commercial value and whether it can establish a new growth curve is still the focus of the capital market's next focus.